72.18
72.18 (0%)
As of Feb 14, 2025
Transmedics Group, Inc. [TMDX]
Source:
Company Overview
Transmedics Group, Inc. is a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide.
| Country | United States |
| Headquarters | andover, massachusetts |
| Phone Number | 9785520900 |
| Industry | manufacturing |
| CEO | Waleed H. Hassanein, M.D. |
| Website | www.transmedics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $441.5 |
| Operating Profit | $37.5 |
| Net Income | $35.5 |
| Net Cash | $-58.2 |
Profit Ratios
| Gross Margin | $262.1 |
| Operating Margin | 8.5 |
| Profit as % of Revenues | 739% |
| Profit as % of Assets | 4.7% |
| Profit as % of Stockholder Equity | 15.5% |
Management Effectiveness
| Return on Equity | 15.5% |
| Return on Assets | 4.4% |
| Turnover Ratio | 58.5% |
| EBITA | $37.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $804.1 |
| Total Liabilities | $575.5 |
| Operating Cash Flow | $48.8 |
| Investing Cash Flow | $-129.3 |
| Financing Cash Flow | $22.9 |
